Join NATF for an exciting new program focused on preventing heart attack, stroke, and leg amputations in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). NATF is inviting patients, physicians, pharmacists, and nurses alike to learn about important updates in vascular protection. Attendees will learn about the intricacies of peripheral artery disease, how to prevent heart attack, stroke, and adverse limb events in patients with atherosclerosis, the important results of the recent COMPASS Trial, and more. Attendees will have the chance to earn up to 2.25 CME credits.
At the end of this program, attendees will be able to:
- Understand the solid rationale for combined anticoagulation and antiplatelet therapy for clinical application based upon advances in translational science.
- Use combination therapy with low-dose anticoagulation and low-dose aspirin to prevent recurrent cardiovascular events in patients with established coronary artery disease or peripheral artery disease.
- Emphasize that carotid atherosclerosis plays a major role in the burden of peripheral artery disease. Secondary prevention with dual antiplatelet therapy and anticoagulation can markedly decrease the risk of stroke.
- Recognize that until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin monotherapy or clopidogrel monotherapy. By adding low-dose anticoagulation to low-dose aspirin, a new era is emerging in which medical therapy can reduce the need for major vascular surgery or endovascular procedures in many patients who otherwise require surgical or endovascular intervention, including reducing drastic measures such as leg amputation.
This program is designed for:
- Patients and caregivers
- Vascular Surgeons
- Vascular Medicine Physicians
- Internal Medicine Physicians
- Nurse Practitioners
- Physician Assistants
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of ScientiaCME and NATF. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians. ScientiaCME designates this educational activity for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s) TM from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)TM.
Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Nurses: May claim credit for activities approved for AMA PRA Category 1 Credit(s)™ in most states for up to 50% of the nursing requirement for recertification. Medical Practice Executives: The American College of Medical Practice Executives accepts AMA PRA Category 1 Credit(s) TM from organizations accredited by ACCME.
Pharmacists: ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 2.25 hours (0.225 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #- 0574-9999-18-003-L01
This course is not valid for CE credit after 6/28/2018. Successful completion of the post-test and completion of the program evaluation is required to obtain a CME certificate.
Additional details for this past event are no longer available.